Prior approval from the Health Insurance Review and Assessment Service will be required to administer the pediatric rickets treatment Crysvita Inj which is set to be reimbursed from May this year.

Accordingly, HIRA has prepared the specifics for Crysvita’s prior approval and applied it from the 3rd of this month.

According to the specific criteria, medical institutions that seek to administer Crysvita’s to children with X-linked hypophosphatemia (XLH), a rare inherited form of rickets, must apply for prior approval to HIRA.

The deliberation will be conducted by the Crysvita subcommittee under the Healthcare Review and Assessment Committee (HCRAC). The subcommittee will